Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.
According to Novo Nordisk's latest financial reports the company's current EPS (TTM) is HK$22.19. In 2022 the company made an earnings per share (EPS) of HK$16.86 an increase over its 2021 EPS that were of HK$15.47.